InVivo Therapeutics Holdings Corp (NVIVQ)

[Analystnueve]

Answer to: What is the current NVIV stock structure?
There are only 26.2M shares in this low-floater which is why the market cap is pretty low for its PPS. Upon reported positive developments, this stock can and has taken off like a banshee.

NASDAQ Global Markets member.

Please also keep in mind that a good number of institutional investors have bought up shares in the $15 and $16 dollar ranges. The current low price is way oversold due to recent macro trends and technical movements only. Now is the time to load up. The institutions will want to see this north of $30. My fair value target is $29 based upon the current developmental fundamentals. However, with additional positive results from patients and encouraging regulatory news, my PT will rise past the mid-thirties. One more noteworthy item to know is the company is in a superb financial condition, with access to as many as four years runway (as much as 1.5 years cash plus additional backup) but is closer to that in getting to revenue stage.